TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Applied DNA Sciences ( (BNBX) ) has shared an announcement.
On November 4, 2025, Applied DNA Sciences entered into an At The Market Offering Agreement with Lucid Capital Markets, allowing the company to sell shares of its common stock valued up to $8,157,932. This agreement, under the company’s shelf registration statement, enables the company to sell shares at market prices, with Lucid Capital Markets acting as the sales agent. The company is not obligated to sell any shares and can suspend or terminate the agreement at any time. This move could potentially impact the company’s financial flexibility and market positioning, although the total proceeds are not determinable at this time.
Spark’s Take on BNBX Stock
According to Spark, TipRanks’ AI Analyst, BNBX is a Neutral.
Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.
To see Spark’s full report on BNBX stock, click here.
More about Applied DNA Sciences
Applied DNA Sciences, Inc. operates in the biotechnology industry, focusing on DNA-based technology solutions. The company provides products and services for supply chain security, anti-counterfeiting, and anti-theft technology, primarily targeting industries such as textiles, pharmaceuticals, and consumer goods.
Average Trading Volume: 1,341,252
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.39M
See more data about BNBX stock on TipRanks’ Stock Analysis page.